PROactive study.
Goldstein
Mark R
MR
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077205:Pioglitazone; D051381:Rats; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone